The iconic rise of Viagra has long been a benchmark of pharmaceutical success, yet its future within the broader industry now triggers questions about potential returns . Copycat versions are eroding market share, prompting worries that supporting companies significantly dependent to Viagra's once-dominant standing could be a speculative read more